We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0VRQ market cap is 5.16B. The company's latest EPS is USD -1.9232 and P/E is -24.90.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 289.59M | 719k | 914.96M | 1.2M | 371.21M |
| Operating Income | 67.31M | -348.06M | 379.53M | -650.5M | -150.72M |
| Net Income | 66.86M | -348.87M | 377.66M | -650.18M | -153.61M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.07B | 1.83B | 2.75B | 2.24B | 2.23B |
| Total Liabilities | 127.33M | 163.73M | 352.42M | 367.58M | 346.77M |
| Total Equity | 939.43M | 1.66B | 2.4B | 1.88B | 1.88B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 56.68M | -238.37M | 538.97M | -495.74M | -260.38M |
| Investing | 1.33M | -541.17M | -1.04B | -258.66M | 374.65M |
| Financing | 430.98M | 1.02B | 250.95M | 38.59M | 62.66M |
| Market Cap | 5.16B |
| Price to Earnings Ratio | -24.90 |
| Price to Sales Ratio | 10.3 |
| Price to Cash Ratio | 9.82 |
| Price to Book Ratio | 2.03 |
| Dividend Yield | - |
| Shares Outstanding | 79.87M |
| Average Volume (1 week) | 5.83k |
| Average Volume (1 Month) | 5.66k |
| 52 Week Change | 0.00% |
| 52 Week High | 64.60 |
| 52 Week Low | 64.60 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Crispr Therapeutics Ag |
| Address |
baarerstrasse 14 zug 6300 |
| Website | https://www.crisprtx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
